Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference

Rhea-AI Summary

Puma Biotechnology, a biopharmaceutical company specializing in cancer care, announced that CEO Alan H. Auerbach will present at the 39th Annual J.P. Morgan Healthcare Conference. The virtual event is scheduled for January 14, 2021, at 7:50 a.m. PST (10:50 a.m. EST). A live webcast will be accessible on Puma’s website and archived for 30 days. Puma focuses on innovative treatments like NERLYNX® (neratinib), approved for certain breast cancer patients, showcasing their commitment to advancing cancer treatment options.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the 39^th Annual J.P. Morgan Healthcare Conference, which will be held virtually. Puma’s presentation will take place at 7:50 a.m. PST (10:50 a.m. EST) on Thursday, January 14, 2021.

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005759/en/

FAQ

What is Puma Biotechnology presenting at the J.P. Morgan Healthcare Conference?

Puma Biotechnology will present an overview of the company led by CEO Alan H. Auerbach at the 39th Annual J.P. Morgan Healthcare Conference.

When is Puma Biotechnology's presentation scheduled?

Puma Biotechnology's presentation is scheduled for January 14, 2021, at 7:50 a.m. PST (10:50 a.m. EST).

Where can I watch Puma Biotechnology's presentation?

You can watch Puma Biotechnology's presentation live on their website, and it will be archived for 30 days.

What is NERLYNX developed by Puma Biotechnology?

NERLYNX (neratinib) is a treatment approved for adult patients with early stage and advanced HER2-positive breast cancer.

What regulatory approvals has NERLYNX received?

NERLYNX was approved by the FDA in 2017 for early stage breast cancer and in 2020 for advanced HER2-positive breast cancer, and it received marketing authorization in Europe in 2018.